Royce & Associates LP Takes $86,000 Position in Oxford Immunotec Global PLC (NASDAQ:OXFD)

Royce & Associates LP purchased a new stake in Oxford Immunotec Global PLC (NASDAQ:OXFD) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,200 shares of the company’s stock, valued at approximately $86,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in OXFD. Man Group plc purchased a new position in Oxford Immunotec Global during the 3rd quarter worth $12,218,000. Millennium Management LLC grew its position in shares of Oxford Immunotec Global by 17.7% during the 3rd quarter. Millennium Management LLC now owns 1,315,387 shares of the company’s stock worth $21,874,000 after buying an additional 197,364 shares in the last quarter. Tocqueville Asset Management L.P. purchased a new position in shares of Oxford Immunotec Global during the third quarter valued at $191,000. Oppenheimer & Co. Inc. increased its stake in shares of Oxford Immunotec Global by 9.9% during the third quarter. Oppenheimer & Co. Inc. now owns 77,400 shares of the company’s stock valued at $1,287,000 after buying an additional 7,000 shares during the period. Finally, Granahan Investment Management Inc. MA increased its stake in shares of Oxford Immunotec Global by 4.4% during the third quarter. Granahan Investment Management Inc. MA now owns 812,227 shares of the company’s stock valued at $13,507,000 after buying an additional 34,263 shares during the period. Hedge funds and other institutional investors own 94.50% of the company’s stock.

A number of analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Oxford Immunotec Global from a “buy” rating to a “hold” rating in a research note on Wednesday, January 8th. BidaskClub raised shares of Oxford Immunotec Global from a “strong sell” rating to a “sell” rating in a research report on Tuesday, February 18th. TheStreet raised shares of Oxford Immunotec Global from a “d+” rating to a “c-” rating in a research report on Tuesday, November 19th. Finally, ValuEngine upgraded shares of Oxford Immunotec Global from a “hold” rating to a “buy” rating in a report on Friday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. Oxford Immunotec Global presently has a consensus rating of “Hold” and a consensus target price of $19.67.

NASDAQ OXFD traded up $0.12 during midday trading on Friday, hitting $14.92. 68,340 shares of the company traded hands, compared to its average volume of 103,897. The company has a debt-to-equity ratio of 0.03, a current ratio of 13.24 and a quick ratio of 12.65. The company has a market cap of $391.41 million, a PE ratio of 11.84 and a beta of 0.42. The company’s 50-day simple moving average is $15.79 and its 200-day simple moving average is $15.53. Oxford Immunotec Global PLC has a 52 week low of $12.49 and a 52 week high of $18.60.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Featured Article: Most Active Stocks

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.